Therapeutic Response

FLT3-ITD status confers therapeutic sensitivity to Midostaurin in patients with Acute Myeloid Leukemia.

Statements

Source and description
Midostaurin Maintenance Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin as a single agent for reimbursement as a treatment option for the maintenance treatment of adult patients with FLT3 mutation positive acute myeloid leukemia (AML) in complete response after completion of induction and consolidation chemotherapy.
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin in combination with intermediate dose cytarabine consolidation chemotherapy for reimbursement as a treatment option for the treatment of adult patients newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation positive